<DOC>
	<DOCNO>NCT02019550</DOCNO>
	<brief_summary>This Phase 4 , prospective , open-label , randomize , cross-over , multicenter trial evaluate ease-of-use Rebif® Rebidose® Rebiject II® autoinjector subject relapse remit multiple sclerosis ( RRMS ) . Subjects participate study 10 week ( include screen treatment period ) . The treatment period last 8 week include 12 self-injections use Rebif® Rebidose® device 12 self-injections use Rebiject II® device .</brief_summary>
	<brief_title>Rebif® Rebidose® Versus Rebiject II® Ease-of-Use</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Interferon beta-1a</mesh_term>
	<criteria>Male female subject , 18 65 year age inclusive , time informed consent signature Diagnosis RRMS Receiving Rebif® , 44 microgram subcutaneously three time week , manual injection least 12 week screen assessment previous use either Rebif® Rebidose® Rebiject II® device acceptable use past 12 week prior study entry , judgment investigator , subject experience user Subject capable selfinjecting use Rebif® Rebidose® Rebiject II® injection device Subject willing able comply study procedure duration trial Signed , inform consent Health Insurance Portability Accountability Act ( HIPAA ) authorization trialrelated activity perform Female subject childbearing potential must negative pregnancy test screening include trial must willing avoid pregnancy use highly effective method contraception Outpatient status time screen Stable disease status without history surgical procedure hospitalization within 30 day prior Study Day 1 , surgical intervention plan duration study Received MS therapy Rebif® within 12 week screen time trial Inadequate liver function bone marrow reserve define protocol Current complete transverse myelitis , bilateral optic neuritis , neuromyelitis optica History injectionsite necrosis within 12 month study entry History alcohol drug abuse past year Any autoimmune disorder , except thyroid disease stable medication Subject moderate severe renal impairment , Investigator 's opinion . Diagnosis primary progressive , secondary progressive , progressive relapse MS Participation another clinical trial within past 30 day interventional trial MS past 12 week Use highdose steroid within 14 day screen Currently experience moderate severe active inflammatory skin disease site expect Rebif® injection History clinically significant lipoatrophy site expect Rebif® injection , investigator 's opinion Current major depression suicidal ideation suicide attempt past year Experiencing spasticity opinion Investigator , could interfere selfinjections Pregnant lactate Inability selfinject visual impairment , opinion Investigator , severe enough , even correction , impede subject 's participation study Upper extremity deficit , opinion Investigator , severe enough impede subject 's participation study Cognitive deficit , opinion Investigator , severe enough impede subject 's participation study Subjectreported reason he/she complete 8week study Any medical condition , opinion Investigator make subject unsuitable study Known hypersensitivity trial treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Multiple Sclerosis , Relapsing-Remitting</keyword>
	<keyword>Rebif®Rebidose®</keyword>
	<keyword>Rebiject II®</keyword>
</DOC>